Genetic Signatures Ltd
ASX:GSS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genetic Signatures Ltd
Net Issuance of Debt
Genetic Signatures Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genetic Signatures Ltd
ASX:GSS
|
Net Issuance of Debt
-AU$455k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Genetic Technologies Ltd
ASX:GTG
|
Net Issuance of Debt
AU$120.5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-25%
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Net Issuance of Debt
-AU$332.9k
|
CAGR 3-Years
-112%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Net Issuance of Debt
-AU$5.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-89%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Net Issuance of Debt
-AU$332k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Net Issuance of Debt
-AU$354.7k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
Genetic Signatures Ltd
Glance View
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
See Also
What is Genetic Signatures Ltd's Net Issuance of Debt?
Net Issuance of Debt
-455k
AUD
Based on the financial report for Dec 31, 2025, Genetic Signatures Ltd's Net Issuance of Debt amounts to -455k AUD.
What is Genetic Signatures Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
-5%
Over the last year, the Net Issuance of Debt growth was -18%. The average annual Net Issuance of Debt growth rates for Genetic Signatures Ltd have been -28% over the past three years , -5% over the past five years .
